Accuray to Showcase New CyberKnife® and TomoTherapy® Technologies at ESTRO 2015
SUNNYVALE, California, April 23, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the company will highlight new CyberKnife® and TomoTherapy® technologies at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain, April 24 – 27, 2015. The CyberKnife and TomoTherapy Systems are used to treat cancerous and benign tumors throughout the body. Each system precisely targets the tumor, delivering the prescribed radiation dose, while minimizing exposure to nearby healthy organs and tissues. At ESTRO, Accuray will showcase:
- The new Delivery Analysis Software for the TomoTherapy System: added confidence for every patient, every fraction, through a new tool that provides unprecedented access to treatment delivery information.
- The InCise™ Multileaf Collimator for the CyberKnife M6™ System: improves treatment efficiency for a broader range of tumor types.
- An enhanced Synchrony® Respiratory Tracking System for the CyberKnife System: makes it even easier for clinicians to know they are precisely tracking and adjusting for moving targets.
- Multiple educational opportunities: thought leaders discuss changes in radiation therapy treatments over the last 30 years during our satellite symposium - titled "Radiation Therapy: Connecting History, Innovation and Patients." A series of presentations from CyberKnife and TomoTherapy users within the Accuray Exchange in Radiation Oncology (AERO™) Academy provides the opportunity to learn about best practices.
- Clinical evidence for both the CyberKnife and TomoTherapy Systems: access to 100 presentations/posters is available on the ESTRO website.
For more information please visit Accuray website.
The new Delivery Analysis Software for the TomoTherapy System
Delivery Analysis for the TomoTherapy System recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), in conjunction with the CE Mark in the European Union. The Delivery Analysis software is an innovative tool that leverages the unique architecture of the TomoTherapy System to provide unprecedented access to treatment delivery information. The software provides enhanced confidence in system performance before each treatment, and actionable insights to help ensure all treatments stay on track. A pre-treatment test of the multileaf collimator (MLC) checks for differences between expected and measured MLC performance using pulse-by-pulse detector signals. Additionally, an in-treatment analysis of each delivered fraction is generated from exit detector data. It allows physicians to see if a particular fraction was not delivered as expected and helps to clarify the nature of the issue that led to the dose miss observed.
An enhanced Synchrony® Respiratory Tracking System for the CyberKnife System
The Synchrony System is the only clinically proven system that uses continual image guidance to automatically adjust the movement of the beam in synchronization with movement of the target volume. This new technology enables clinicians to:
- Improve their ability to track moving targets and minimize treatment margins.
- Confidently set up Synchrony Respiratory Tracking with just a few mouse clicks.
- Set up and treat moving targets, in particular lung cases, faster and more easily.
Satellite Symposium: "Radiation Therapy: Connecting History, Innovation and Patients"
The symposium will be held on Saturday, 25 April 2015 from 13:15 to 14:30, room 111 (level 1). Presentations will explore the progress that has been made over the last 30 years in radiation therapy and discuss Accuray's contribution to setting the standard for the precise treatments that are used today and will be used in the future. Chaired by Prof. Jurgen Peter Debus, M.D., Ph.D., Managing Director of the Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, Symposium speakers will include: Dr. Cary Adams, CEO, the Union for International Cancer Control (UICC) and Chair of the NCD Alliance in Geneva, Switzerland; Prof. Ben J.M. Heijmen, Ph.D., Head of the Section of Medical Physics, Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands; and Prof. Thomas Rockwell Mackie, Ph.D., Emeritus Professor, Departments of Medical Physics and Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in and future contributions to radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Share this article